IMRX Immuneering
- 1.480
- +0.010+0.68%
- 1.490
- +0.010+0.68%
Immuneering News
Express News | Needham Reiterates Buy on Immuneering, Maintains $15 Price Target
Analysts' Opinions Are Mixed on These Healthcare Stocks: Enlivex (ENLV), MacroGenics (MGNX) and Immuneering (IMRX)
Immuneering Presented Preclinical Data At AACR Annual Meeting For Ongoing Phase 2a Clinical Trial Of IMM-1-104 In RAS-Mutated Advanced Or Metastatic Solid Tumors
Globe Newswire- Preclinical data presented at AACR demonstrate that combining IMM-1-104 with chemotherapies used in the treatment of first-line pancreatic cancer yielded deeper and more durable tumor
IMM-1-104 Is Synergistic With Chemotherapy in Pancreatic Cancer Models
CAMBRIDGE, Mass., April 09, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad populations of cancer patients, today presented preclinical data at the American Association for Cancer Research (AACR) Annual Meeting, which the company views as supportive of its ongoing Phase 2a clinical trial of IMM-1-104 in RAS-mutated advanced or metastatic solid tumors.
Immuneering(IMRX.US) 10% Shareholder Sells US$1.16 Million in Common Stock
$Immuneering(IMRX.US)$ 10% Shareholder Cormorant Asset Management, LP sold 400K shares of Common Stock on Apr 1, 2024 at an average price of $2.9 for a total value of $1.16 million. This transaction i
Immuneering to Participate in the 23rd Annual Needham Virtual Healthcare Conference
PDF Version CAMBRIDGE, Mass., April 03, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF
Immuneering Is Maintained at Buy by Mizuho
Immuneering Is Maintained at Buy by Mizuho
Immuneering Price Target Cut to $8.00/Share From $20.00 by Mizuho
Immuneering Price Target Cut to $8.00/Share From $20.00 by Mizuho
Immuneering Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/02/2024 190.91% Mizuho $20 → $8 Maintains Buy 03/15/2024 9.09% Jefferies $16 → $3 Downgrades Buy → Hold
Buy Rating Affirmed for Immuneering on Solid Trial Progress and Insider Confidence
Express News | Immuneering Shares Are Trading Higher. The Company Yesterday Announced That the First Patient Has Been Dosed in Its Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors With RAF or RAS Mutations
Insider Spends US$183k Buying More Shares In Immuneering
Investors who take an interest in Immuneering Corporation (NASDAQ:IMRX) should definitely note that the Director, Peter Feinberg, recently paid US$2.44 per share to buy US$183k worth of the stock.
Immuneering Announces First Patient Dosed In Its Phase 1/2a Trial Of IMM-6-415 To Treat Advanced Solid Tumors With RAF Or RAS Mutations
- Deep Cyclic Inhibitor of the MAPK pathway demonstrated strong tumor growth inhibition in preclinical studies of RAF or RAS mutant tumors, both as monotherapy and in combination -- Phase 1 portion of
Immuneering Announces First Patient Dosed in Its Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors With RAF or RAS Mutations
Immuneering Corporation (Nasdaq: IMRX) today announced that the first patient has been dosed in its Phase 1/2a trial of IMM-6-415 to treat advanced solid tumors with RAF or RAS mutations.
Immuneering(IMRX.US) Director Buys US$7,384.85 in Common Stocks
$Immuneering(IMRX.US)$ Director Schall Thomas J. purchased 2,900 shares of Common Stocks on Mar 22, 2024 at an average price of $2.5465 for a total value of $7,384.85.Source: Announcement What is stat
Immuneering(IMRX.US) Director Buys US$63,712.5 in Common Stocks
$Immuneering(IMRX.US)$ Director Feinberg Peter purchased 25,000 shares of Common Stocks on Mar 22, 2024 at an average price of $2.5485 for a total value of $63,712.5.Source: Announcement What is state
Immuneering(IMRX.US) Officer Buys US$10,015.2 in Common Stocks
$Immuneering(IMRX.US)$ Officer Brakewood Harold Eugene purchased 3,900 shares of Common Stocks on Mar 22, 2024 at an average price of $2.568 for a total value of $10,015.2.Source: Announcement What is
Immuneering(IMRX.US) Officer Buys US$4,009.1 in Common Stocks
$Immuneering(IMRX.US)$ Officer Morales Mallory purchased 1,500 shares of Common Stocks on Mar 21, 22, 2024 at an average price of $2.6727 for a total value of $4,009.1.Source: Announcement What is sta
STEM, SOUN and GRFS Among Pre-market Losers & Stocks
Immuneering(IMRX.US) Officer Buys US$10,993.17 in Common Stocks
$Immuneering(IMRX.US)$ Officer Neufeld Leah R purchased 3,818 shares of Common Stocks on Mar 20, 2024 at an average price of $2.8793 for a total value of $10,993.17.Source: Announcement What is statem
Analysis
Price Target
No Data
